Ticagrelor is a reversible inhibitor of P2Y\(_{12}\) ADP receptors, unlike clopidogrel and prasugrel, which bind irreversibly.
It prevents platelet aggregation, reducing thrombosis risk in acute coronary syndrome patients.
Ticagrelor offers faster onset and shorter duration, allowing controlled antiplatelet effects.